<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251536</url>
  </required_header>
  <id_info>
    <org_study_id>S51532</org_study_id>
    <secondary_id>2009-009992-36</secondary_id>
    <nct_id>NCT01251536</nct_id>
  </id_info>
  <brief_title>Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer</brief_title>
  <acronym>Everest2</acronym>
  <official_title>A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine whether administering escalating doses of
      cetuximab in patients with no early skin toxicity could delay the progression of disease in a
      significant proportion of patients and to study the molecular signatures of response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal carcinoma (CRC) is the third most common form of cancer worldwide and remains a
      leading malignancy both in incidence and mortality.

      In the light of existing knowledge, the investigators propose a phase II open label, two arm
      study in patients presenting with K-Ras wild-type metastatic colorectal tumours in the first
      line setting. The standard combination of irinotecan plus infusional 5-FU/LV (FOLFIRI) and
      cetuximab will be given to all patients entering the study. As the investigators hypothesize
      that increasing the dose of cetuximab might increase the intensity of skin reactions that
      directly correlates with outcome, in patients experiencing no skin toxicity, the dose of
      cetuximab will be escalated from 250 mg/m2 to 350 mg/m2 and then up to 500 mg/m2, in order to
      better define the effect of dose escalation in the first-line setting in a K-Ras wild type
      tumour population and in an attempt to increase efficacy.

      Pharmacokinetic studies will be performed to document PK parameters of cetuximab in patients
      from both arms in selected centers.

      Translational research studies are planned for all patients. Some more in depth molecular
      testing will be performed in a subset of patients from whom three serial tissue samples from
      accessible metastases by biopsy are available.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS rate at 9 months in the dose escalation arm</measure>
    <time_frame>9 months</time_frame>
    <description>To provide a precise estimate (+/- 10%) of the progression-free survival rate at 9 months, in patients without skin toxicity at 3 weeks (according to NCI CTCAE v. 4.0), treated with FOLFIRI + escalating dose of cetuximab (arm A). It is expected that the PFS rate will be similar to that observed after standard cetuximab treatment + FOLFIRI in patients with grade 1-4 skin toxicity in a K-Ras wild type population (CRYSTAL study)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile (NCI-CTCAE v. 4.0) of the combination in treatment arms</measure>
    <time_frame>3.5 years</time_frame>
    <description>To evaluate PFS, OS, overall response and response rate in liver-limited disease, disease control rate, duration of response, general resection rate and R0 resection rate for metastatic lesions, skin toxicity, general safety, biomarkers, proteomics, expression profiling, mutations in each of the treatment arms.
To evaluate pharmacokinetic parameters in patients in both treatment arms in selected centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin toxicity and correlations between outcome, PK and dose escalations</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response and response rate in liver-limited disease</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rates</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and overall survival</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate for metastatic lesions</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters in patients in both treatment arms in selected centers only</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform biomarker analyses: proteomics, microarray and PCR studies on plasma and tumour respectively, in both treatment arms.</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm B - standard dose of cetuximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A - dose escalation of cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose escalation of cetuximab</intervention_name>
    <description>Dose, frequency &amp; treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly</description>
    <arm_group_label>Arm A - dose escalation of cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard first line treatment with cetuximab + Folfiri</intervention_name>
    <description>Dose, frequency &amp; treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.</description>
    <arm_group_label>Arm B - standard dose of cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent (+ optional for PK and TR) must be given according to ICH/GCP
             and national/local regulations.

          2. Patient is at least 18 years of age.

          3. Patient's body weight is ≤ 120 kg.

          4. Histologically proven and measurable (RECIST criteria v.1.1) metastatic adenocarcinoma
             of the colon or rectum, not in a previously irradiated area.

          5. K-Ras wild type tumour eligible for treatment with cetuximab.

          6. Unresectable metastatic disease.

          7. Life expectancy of at least 12 weeks.

          8. WHO ECOG performance status: 0 or 1.

          9. Effective contraception for both male and female patients if the risk of conception
             exists.

         10. Adequate organ function.

         11. Adequate bone marrow, hepatic and renal function (assessed within 14 days prior to
             study entry):

               -  Hemoglobin &gt; 10.0 g/dL, absolute neutrophil count &gt; 1.5 x 109/L, platelet count &gt;
                  100 x 109/L

               -  ALAT, ASAT &lt; 2.5 x ULN, up to &lt; 5 x ULN in case of liver metastases

               -  Alkaline phosphatase &lt; 2.5 x ULN

               -  Total bilirubin &lt; 1.5 x ULN

               -  Creatinine clearance &gt; 50 mL/min (calculated according to Cockroft and Gault)

        Exclusion Criteria:

          1. Prior treatment for metastatic disease (adjuvant therapy with fluoropyrimidines
             +/-oxaliplatin based regimens allowed if stopped 6 months prior to registration on
             study).

          2. Prior treatment with EGFR inhibitor or chemotherapy with irinotecan in adjuvant
             settings.

          3. Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
             entry.

          4. Administration of any investigational drug or agent/procedure, i.e. participation in
             another trial within 4 weeks before beginning treatment.

          5. Concurrent chronic systemic immune therapy, chemotherapy, radiation therapy or hormone
             therapy not indicated in the study protocol.

          6. Any active dermatological condition &gt; grade 1.

          7. Brain metastasis (known or suspected).

          8. Significant impairment of intestinal absorption (e.g. chronic diarrhea, inflammatory
             bowel disease).

          9. Other uncontrolled concomitant illness, including serious uncontrolled intercurrent
             infection.

         10. Uncontrolled coronary artery disease and/or unstable angina, a history of a myocardial
             infarction within the last 12 months or heart failure NYHA class III or IV. High risk
             of uncontrolled arrhythmia.

         11. Known allergy or any other adverse reaction to any of the drugs or to any related
             compound.

         12. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

         13. Gilbert disease.

         14. Previous (within 5 years) or concurrent malignancies at other sites with the exception
             of surgically cured or adequately treated carcinoma in-situ of the cervix and basal
             cell carcinoma of the skin.

         15. Organ allografts requiring immunosuppressive therapy.

         16. Pregnancy (absence confirmed by serum/urine beta human choriongonadotrophin in
             pre-menopausal women) or breast-feeding.

         17. Medical, social or psychological condition which, in the opinion of the investigator,
             would not permit the patient to complete the study or sign meaningful informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Cutsem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Innere medizin, Klinishe abteilung für hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Leoben, abteilung f. innere Medizin</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinishe Onkologie</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg, Univ. Klinik für innere Medizin III, Universitätsklinikum der PMU</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung, 1 medizinishe Abteilung</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Krankenhaus Betriebs GmbH</name>
      <address>
        <city>Zams</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Middelares Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Jolimont-Lobbes, Oncology Médicale</name>
      <address>
        <city>Haine Saint Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Saint Joseph</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Maarten Mechelen/Duffel</name>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout (Campus St Elisabeth)</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicennes</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the University of Pecs</name>
      <address>
        <city>National Institute Oncology</city>
        <state>Budapest</state>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Center</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario De Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>K-Ras wildtype</keyword>
  <keyword>first line metastatic</keyword>
  <keyword>standard cetuximab + FOLFIRI</keyword>
  <keyword>dose escalation cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

